238 related articles for article (PubMed ID: 30664602)
21. Does 18F-FDG PET/MRI reduce the number of indeterminate abdominal incidentalomas compared with 18F-FDG PET/CT?
Schaarschmidt BM; Grueneisen J; Heusch P; Gomez B; Umutlu L; Ruhlmann V; Rosenbaum-Krumme S; Antoch G; Buchbender C
Nucl Med Commun; 2015 Jun; 36(6):588-95. PubMed ID: 25759944
[TBL] [Abstract][Full Text] [Related]
22. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
[TBL] [Abstract][Full Text] [Related]
23. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of 18F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type.
Liu C; Zhang Y; Zhang Y; Wang M; Liu R; Liu X; Hu S
Nucl Med Commun; 2016 May; 37(5):446-52. PubMed ID: 26657218
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis and risk factors of advanced colorectal neoplasms incidentally detected by 18F-FDG PET-CT.
Chung SM; Kim KO; Cho IH; Kim TN
Eur J Gastroenterol Hepatol; 2017 Apr; 29(4):407-413. PubMed ID: 27926665
[TBL] [Abstract][Full Text] [Related]
26. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of
Jung JH; Lee SW; Son SH; Kim CY; Lee CH; Jeong JH; Jeong SY; Ahn BC; Lee J
Head Neck; 2017 Mar; 39(3):447-455. PubMed ID: 27726225
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of 18F-FDG PET/contrast-enhanced CT versus contrast-enhanced CT alone for post-treatment detection of ovarian malignancy.
Tawakol A; Abdelhafez YG; Osama A; Hamada E; El Refaei S
Nucl Med Commun; 2016 May; 37(5):453-60. PubMed ID: 26745811
[TBL] [Abstract][Full Text] [Related]
29. Role of
Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
[TBL] [Abstract][Full Text] [Related]
30. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
31. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
32. Utility of FDG PET/CT for assessment of lung nodules identified during low dose computed tomography screening.
Hadique S; Jain P; Hadi Y; Baig A; Parker JE
BMC Med Imaging; 2020 Jun; 20(1):69. PubMed ID: 32571221
[TBL] [Abstract][Full Text] [Related]
33. Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients.
Uyl-de Groot CA; Senft A; de Bree R; Leemans CR; Hoekstra OS
J Nucl Med; 2010 Feb; 51(2):176-82. PubMed ID: 20124045
[TBL] [Abstract][Full Text] [Related]
34. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
35. Application of PET and PEt/CT imaging for cancer screening.
Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
[TBL] [Abstract][Full Text] [Related]
36. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
Xiao Y; Wang L; Jiang X; She W; He L; Hu G
Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
[TBL] [Abstract][Full Text] [Related]
38. Role of
Lopez-Lopez V; Robles R; Brusadin R; López Conesa A; Torres J; Perez Flores D; Navarro JL; Gil PJ; Parrilla P
Br J Radiol; 2018 Jan; 91(1081):20170216. PubMed ID: 29034693
[TBL] [Abstract][Full Text] [Related]
39. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
40. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]